What's Going On With Eli Lilly Stock Thursday?

Zinger Key Points
  • Eli Lilly has settled a lawsuit filed by Minnesota, accusing major insulin manufacturers of deceptive price increases.
  • Eli Lilly expects fiscal year 2024 sales of $40.4 billion-$41.6 billion, a jump of almost 20% Y/Y.

Since Monday, Eli Lilly And Co LLY shares have gained 8%, closing at $724.85 on Wednesday, sending the market capitalization to a whopping $690 billion (roughly).

Thursday, shares are trading with a session volume of 25.301K compared to an average volume of 3.277 million, as per data from Benzinga Pro.

Tuesday, the company released much-awaited, better-than-expected fourth-quarter results. Eli Lilly expects fiscal year 2024 sales of $40.4 billion-$41.6 billion versus the consensus of $39.14 billion and fiscal year 2023 sales of $34.12 billion.

During CNBC’s ‘Halftime Report,’ the committee noted that “in the instance of Eli Lilly, there is more to go in the stock.”

  • BMO Capital raised the price target from $710 to $865
  • BofA Securities raised the price target to $800, up from $750.
  • Wells Fargo maintained an Overweight and raised the price target from $700 to $825.
  • Barclays reiterated an Overweight rating and raised the price target from $680 to $810.
  • Morgan Stanley maintained the Overweight rating with a price target up from $763 to $805.
  • Truist Securities maintained the Buy rating and raised the price target from $650 to $850.

Eli Lilly has settled a lawsuit filed by Minnesota, accusing major insulin manufacturers of deceptive price increases. 

As part of the settlement, Reuters noted that Eli Lilly will provide low-cost insulin to patients and donate free insulin to 15 clinics in Minnesota. 

In Minnesota, paying out-of-pocket patients can access Eli Lilly’s insulin products for a maximum of $35 per month. Even those with insurance can opt to pay $35 instead of using their coverage. 

The settlement, effective for five years, aims to address the affordability of life-sustaining insulin. 

The lawsuit, initiated by Minnesota in 2018, is still pending against Novo Nordisk A/S NVO and Sanofi SA SNY

In March of the previous year, Eli Lilly had already committed to reducing insulin prices, offering it to many patients at $25 or $35.

Price Action: LLY shares are up 1.91% at $739.15 on the last check Thursday.

Photo by rafapress on Shutterstock

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareMoversTrading IdeasGeneralBriefsStories That Matterwhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!